Braidwell’s Karyopharm Therapeutics KPTI Stock Holding History

Braidwell’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-303,370	Closed	-$2.23M	–	94
2025 Q4	$2.23M	Buy	+303,370	New	+$1.86M	0.07%	72

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Braidwell's KPTI Position: Q1 2026 in Review

Braidwell sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 303,370 shares — an estimated $2.23M sold.

Braidwell first reported a position in KPTI in Q4 2025 and held it in 1 quarter. The position peaked at $2.23M in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

Braidwell reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
Braidwell sold 303,370 Karyopharm Therapeutics shares in Q1 2026, an estimated $2.23M.
Braidwell first reported a position in Karyopharm Therapeutics in Q4 2025 and held it in 1 quarter.
Braidwell's Karyopharm Therapeutics position peaked at $2.23M in Q4 2025.
77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.